Danaher Co. (NYSE:DHR) Shares Acquired by Anchor Investment Management LLC

Anchor Investment Management LLC lifted its position in Danaher Co. (NYSE:DHR) by 1.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,039 shares of the conglomerate’s stock after acquiring an additional 78 shares during the period. Anchor Investment Management LLC’s holdings in Danaher were worth $1,679,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in DHR. CarsonAllaria Wealth Management Ltd. purchased a new stake in shares of Danaher in the second quarter valued at approximately $25,000. nVerses Capital LLC acquired a new position in Danaher during the second quarter worth $25,000. Teachers Insurance & Annuity Association of America purchased a new stake in Danaher in the 3rd quarter valued at $39,000. MidAtlantic Capital Management Inc. acquired a new stake in shares of Danaher in the 3rd quarter worth $40,000. Finally, FSA Wealth Management LLC purchased a new position in shares of Danaher during the 3rd quarter worth $50,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Stock Performance

Shares of DHR stock opened at $234.50 on Friday. Danaher Co. has a 12 month low of $219.15 and a 12 month high of $281.70. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The company has a market cap of $169.37 billion, a P/E ratio of 44.75, a PEG ratio of 4.33 and a beta of 0.83. The firm has a fifty day moving average price of $248.34 and a 200 day moving average price of $257.78.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The business had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.02 EPS. Sell-side analysts predict that Danaher Co. will post 7.5 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be given a dividend of $0.27 per share. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.46%. Danaher’s dividend payout ratio is presently 20.61%.

Analysts Set New Price Targets

Several research firms recently issued reports on DHR. Stephens restated an “overweight” rating and set a $315.00 price objective on shares of Danaher in a research report on Wednesday, October 23rd. Wells Fargo & Company started coverage on shares of Danaher in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price target on the stock. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a report on Thursday, December 5th. Barclays cut their target price on Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 23rd. Finally, Robert W. Baird lowered their price target on Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $287.16.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.